DelveInsight’s, “Primary Sclerosing Cholangitis Pipeline Insight, 2022,” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in the Primary Sclerosing Cholangitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Primary Sclerosing Cholangitis Pipeline Report
Recent Developmental Activities in the Primary Sclerosing Cholangitis Pipeline
Request a sample and discover the recent breakthroughs happening in the Primary Sclerosing Cholangitis pipeline landscape @ Primary Sclerosing Cholangitis Pipeline Outlook
Primary Sclerosing Cholangitis Overview
Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extrahepatic bile ducts. The condition may lead to cirrhosis of the liver with portal hypertension and end-stage liver disease (ESLD). The main symptoms of primary sclerosing cholangitis (PSC) are feeling tired or weak and having itchy skin. Other symptoms may include losing weight without trying, poor appetite, fever, and pain in the abdomen. The cause of PSC is not known. A diagnosis of primary sclerosing cholangitis is made based upon a thorough clinical evaluation, a detailed patient history, identification of characteristic findings, and a variety of specialized tests. Diagnosis is done by cholangiography (magnetic resonance cholangiopancreatography [MRCP] or endoscopic retrograde cholangiopathy [ERCP]). Treatments for primary sclerosing cholangitis focus on managing complications and monitoring liver damage. Endoscopic surgery to remove blockages and enlarge narrowed bile ducts may be of benefit to help prevent liver deterioration in certain cases. Lost vitamins should be replaced when required to prevent complications related to these deficiencies.
Primary Sclerosing Cholangitis Emerging Drugs
GS-9674: Gilead Sciences
GS-9674 (Cilofexor) is an orally active, small molecule based nonsteroidal FXR agonist. The drug is in Phase III clinical studies for the treatment of Primary sclerosing cholangitis.
IMU-838: Immunic
IMU-838 is a small molecule investigational drug (vidofludimus calcium) under development as an oral tablet formulation for the treatment PSC. The drug is in clinical studies for the treatment of Relapsing-Remitting Multiple Sclerosis, Progressive Multiple Sclerosis, Ulcerative Colitis, Crohn’s Disease, and Primary Sclerosing Cholangitis. The drug is in Phase II clinical studies for the treatment of Primary sclerosing cholangitis.
Primary Sclerosing Cholangitis Pipeline Therapeutic Analysis
There are approx. 14+ key companies which are developing the therapies for Primary Sclerosing Cholangitis. The companies which have their Primary Sclerosing Cholangitis drug candidates in the most advanced stage, i.e. Phase III include, Gilead Sciences.
Find out more about Primary Sclerosing Cholangitis treatment @ Primary Sclerosing Cholangitis Clinical Trials
Primary Sclerosing Cholangitis Pipeline Therapeutics Assessment
The Primary Sclerosing Cholangitis Pipeline report proffers an integral view of the Primary Sclerosing Cholangitis emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.
Scope of the Primary Sclerosing Cholangitis Pipeline Report
Dive deep into rich insights for drugs for Primary Sclerosing Cholangitis, visit @ Primary Sclerosing Cholangitis Emerging Therapies
Table of Content
Key Questions
Current Treatment Scenario and Emerging Therapies:
For further information on the Primary Sclerosing Cholangitis pipeline therapeutics, reach out to Primary Sclerosing Cholangitis Treatment Landscape
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/